HK Stock Market Move | JW THERAP-B(02126) surges over 9% in early trading, Beinuoda included in the national medical insurance bureau's commercial insurance innovative drug catalog.

JW THERAP-B (02126) rose by more than 9% in early trading, up 7.79% as of press time, reaching HK$3.32 with a turnover of HK$2.6756 million. On the news front, according to a message from JW THERAP-B's official WeChat account, on December 7th, the company announced that its first China-developed and newly approved Class 1 CAR-T product, Bionda (ruojiaolunsa injection), has been successfully included in the first edition of the National Medical Insurance Administration's commercial health insurance innovative drug catalog. Bionda is currently the only CAR-T product in China approved for three indications of non-Hodgkin's lymphoma (including relapsed/refractory large B-cell lymphoma, relapsed/refractory follicular lymphoma, and relapsed/refractory T-cell lymphoma). Prior to the establishment of the national commercial insurance innovation drug catalog, Bionda had already been included in more than 100 basic medical insurance and nearly 100 million medical insurance policies, and has been extensively validated through numerous clinical practices and real-world studies among Chinese patients.